Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.
about
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarctionApplications of CYP450 testing in the clinical settingAn acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Ethnicity-specific pharmacogenetics: the case of warfarin in African AmericansExtending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trialGenetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.Pharmacogenetics guided anticoagulation.Genetic determinants of variability in warfarin response after the dose-titration phase.Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
P2860
Q24311573-25AE016D-92E2-4460-AE5B-0BEC83B7EBF1Q24621760-975AE5AE-9ECE-4AA2-AE44-BB37351A04F4Q30558676-AA387CF2-BF0D-4FD6-9B12-F0DD3E99624AQ33591111-1ECBA8E8-926E-474D-91E1-52211079E0D8Q34994877-6F49F182-E990-4FB2-BF15-06D3EB43EFEAQ36527206-44006CA6-ECCF-40FC-BFE4-BED62F0849F6Q36813817-51574A65-D72C-44FC-9F54-384A8BA1FB1AQ37808224-EFC57B01-2AB2-4060-BA7D-1BA4C57477F1Q43113299-AC0143DF-D594-486C-B12C-7DFBEB1C2A9DQ45749835-5975EAAE-EE1B-45B1-9D17-22C44ECA0412Q46747889-D635E620-C4DA-425A-A2D9-C04FF5F1F7E9Q51134013-90186DC0-8455-41DB-B50A-D9B35698F510Q51337900-99A85C60-6B91-47AD-B5B7-B94A3121E83EQ51739644-190C0EA1-EF88-43FA-9536-259172F7B7D3Q53088047-0D67D271-F7C4-498A-96DC-A0215095A8FA
P2860
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@en
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@nl
type
label
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@en
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@nl
prefLabel
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@en
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@nl
P2093
P2860
P1433
P1476
Effects of CYP2C9 and VKORC1 o ...... hase of anticoagulant therapy.
@en
P2093
Corrado Lodigiani
Denise Pizzotti
Fr Rosendaal
Lidia L Rota
Marta Spreafico
Y van Leeuwen
P2860
P304
P356
10.2217/14622416.9.9.1237
P577
2008-09-01T00:00:00Z